Akebia Therapeutics (AKBA) Other Non Operating Income (2013 - 2026)

Akebia Therapeutics (AKBA) has 13 years of Other Non Operating Income data on file, last reported at $3000.0 in Q1 2026.

• Other Non Operating Income for Q1 2026 came in at $3000.0, down 98.59% year-over-year; the trailing twelve-month figure through Mar 2026 was -$210000.0 (up 41.67% YoY), and the FY2024 annual result was -$517000.0, down 158.29% from the prior year.
• Other Non Operating Income climbed to $3000.0 in Q1 2026 per AKBA's latest filing, from -$175000.0 in the prior quarter.
• Over five years, Other Non Operating Income peaked at $1.2 million in Q3 2022 and troughed at -$3.6 million in Q4 2022.
• A 5-year average of -$16562.5 and a median of -$3500.0 in 2023 frame the typical range for Other Non Operating Income.
• On a YoY basis, Other Non Operating Income climbed as much as 604.35% in 2022 and fell as far as 249.88% in 2022.
• A 5-year view of Other Non Operating Income shows it stood at -$3.6 million in 2022, then jumped by 124.52% to $887000.0 in 2023, then plunged by 162.68% to -$556000.0 in 2024, then surged by 68.53% to -$175000.0 in 2025, then surged by 101.71% to $3000.0 in 2026.
• Business Quant data shows AKBA's Other Non Operating Income at $3000.0 in Q1 2026, -$175000.0 in Q4 2025, and -$10000.0 in Q3 2025.